Epigenetics in Psychiatry, Second Edition covers all major areas of psychiatry in which extensive epigenetic research has been performed, fully encompassing a diverse and maturing field, including drug addiction, bipolar disorder, epidemiology, cognitive disorders, and the uses of putative epigenetic-based psychotropic drugs. Uniquely, each chapter correlates epigenetics with relevant advances across genomics, transcriptomics, and proteomics. The book acts as a catalyst for further research in this growing area of psychiatry. This new edition has been fully revised to address recent advances in epigenetic understanding of psychiatric disorders, evoking data consortia (e.g., CommonMind, ATAC-seq), single cell analysis, and epigenome-wide association studies to empower new research. The book also examines epigenetic effects of the microbiome on psychiatric disorders, and the use of neuroimaging in studying the role of epigenetic mechanisms of gene expression. Ongoing advances in epigenetic therapy are explored in-depth.

Neuropsychiatric Disorders and Epigenetics is a comprehensive reference for the epigenetic basis of most common neuropsychiatric disorders. The volume is organized into chapters representing individual neuropsychiatric disorders, from addition to obesity contributed by leading experts in their respective fields. The epigenetic aspects of each disorder are discussed, in the context of the full range of epigenetic mechanisms including DNA modification, histone post-translational modification, chromatin organization and non-coding RNA. A particular emphasis is placed on potential epigenetic interventions, when the effects of environmental stimuli on epigenetic states is particularly relevant o disease. Recent discoveries in epigenetic research enabled by epic advances in genomic technologies have positioned the field for broad translation to therapeutic interventions for previously unmanageable disorders Neuropsychiatric disorders represent a prime target of epigenetic interventions as they are highly debilitating, often chronic diseases with enormous costs to society. Thus, this volume will help define epigenetics as a key player in neuropsychiatric disorders, highlighting the full spectrum of epigenetic mechanisms underlying such disorders and introducing the vast range of epigenetic therapies under development.

Epigenetics and Psychiatric Disease, Volume 157, the latest volume in the Progress in Molecular Biology and Translational Science series, includes recent developments on a variety of topics, including the Epigenetic landscapes of the adversity-exposed brain, Chromosomal conformations and epigenomic regulation in schizophrenia, Progress in the epigenetics of depression, the epigenetics of circadian rhythms in imprinted neurodevelopmental disorders, DNA methylation mediating substance abuse, mechanisms and therapeutic opportunities, DNA methylation in animals model of psychosis, Epigenetics of early life stress, Epigenetic drugs for mood disorders, and more.

Neuropsychiatric Disorders and Epigenetics, Second Edition is a comprehensive reference on the epigenetic basis of common neuropsychiatric disorders. The volume is organized into chapters covering individual neuropsychiatric disorders, from addiction to anxiety and autism spectrum disorders, and is contributed by leading experts in their respective fields. The epigenetic aspects of each disorder are discussed, in the context of the full range of associated epigenetic mechanisms, including DNA modification, histone post-translational modification, chromatin organization, and non-coding RNA. A particular emphasis is placed on potential epigenetic interventions, when the effects of environmental stimuli on epigenetic states is particularly relevant to disease. This new edition has been fully updated to reflect recent research advances enabled by genomic technologies, as well as therapeutic interventions for previously unmanageable disorders. Several new chapters have been added on disorders or approaches not considered in the earlier edition, including epigenetics and anxiety disorders, epigenetics and neuroimaging in neuropsychiatric disorders, genome-wide approaches to epigenetic research, and the epigenetics of spinal muscular atrophy. By helping to define epigenetics as a key player in neuropsychiatric disorders, this volume empowers new research, clinical translation, and pharmacological advances, and highlights promising directions for ongoing investigation.